Related Experiment Video
Updated: Aug 15, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Rituximab in progressive connective tissue disease-associated interstitial lung disease: A multicenter real-world
Agustín Patrone1, Juan Ignacio Enghelmayer2, María Otaola3
1Interstitial Disease Unit, Sanatorio Güemes University Hospital, Buenos Aires, Argentina.
Respiratory Medicine
|August 13, 2026
Summary
Rituximab stabilized lung function in patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) refractory to other treatments. This rescue therapy showed sustained improvements in forced vital capacity (FVC) and DLCO over 12 months.
Area of Science:
- Pulmonology
- Rheumatology
- Immunology
Background:
- Connective tissue disease-associated interstitial lung disease (CTD-ILD) is challenging to treat.
- Rituximab is a potential rescue therapy for CTD-ILD resistant to standard immunosuppression.
- Real-world data on long-term rituximab efficacy in CTD-ILD are limited.
Purpose of the Study:
- To evaluate the long-term lung function trajectories in patients with progressive CTD-ILD treated with rituximab.
- To assess rituximab's efficacy as a rescue therapy in a real-world setting.
Main Methods:
- Multicenter retrospective cohort study.
- Included patients with progressive CTD-ILD despite mycophenolate mofetil or cyclophosphamide.
- Defined progression as ≥10% decline in forced vital capacity (FVC) over 6 months.
- Pulmonary Function Tests (PFTs) assessed at baseline, early post-rituximab, and 12 months.
Main Results:
- Fifty-eight patients were analyzed.
- Mean FVC declined 15.8% in the 6 months prior to rituximab.
- Mean FVC increased 4.7% early post-rituximab and 6.8% at 12 months (p < 0.001).
- Mean DLCO also showed a significant 12-month increase (p = 0.018).
- Improvements were more frequent in inflammatory-predominant phenotypes and patients with higher baseline FVC.
- Rituximab had a favorable safety profile.
Conclusions:
- Rituximab demonstrated early stabilization and persistent lung function response in progressive CTD-ILD over 12 months.
- Clinical benefit may be greater in inflammatory phenotypes and patients with preserved lung volumes.
- Rituximab is a viable rescue therapy for select CTD-ILD patients, warranting further prospective validation.
Related Concept Videos
01:22Connective Tissue Cell Types
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...